reports
Thymidine Kinase 1 can be used for early detection of therapy response...
Thymidine Kinase 1 can be used for early detection of therapy response in breast cancer treatment Patients treated with Epirubicin and Docetaxel before surgery were followed by their thymidine kinase (TK1) levels in blood to directly observe treatment response. The results show that a TK1-based cell-loss metric after two cycles of therapy predicted the status at the operation after six cycles of chemotherapy. The metric predicted early on whether or not the chemotherapy works. The purpose with this PROMIX study is to investigate whether a cell-loss metric, defined as the ratio between s...
AroCell expands with a Regulatory Affairs Director
AroCell expands with a Regulatory Affairs Director AroCell AB (publ.) announces today that Peter Löwendahl joins the management team as senior director regulatory affairs. Peter Löwendahl will lead and develop AroCell’s regulatory strategy with focus on the US market and FDA clearance of our TK 210 ELISA. Peter Löwendahl has almost 30 years of experience in quality and regulatory affairs and has previously been responsible for Quality and Regulatory affairs at Elekta AB and global regulatory responsibility for GE Healthcare's Life science division. In the last 3 years, he works mainly as a...
AroCell AB (publ) Interim Report January 1st to June 30th 2019
AroCell AB (publ) Interim Report January 1st to June 30th 2019 Word from the CEO “It is with pleasure that I can say that the second quarter of 2019 became one of the most exciting and active quarters in AroCell's history. The goal of establishing AroCell as the given partner and supplier of a reliable method for measuring Thymidine kinase 1 in the blood permeates everything we do. During the quarter, we increased sales, signed more distributor agreements, signed a collaboration agreement with CLIA lab in the US and started a collaboration with the Dana Farber Cancer Institute in the USA...
AroCell signs a new distributor agreement in the USA and Canada
AroCell signs a new distributor agreement in the USA and Canada AroCell AB (publ) announced today that it has signed a distribution agreement with Diapharma Group of West Chester Ohio for the promotion and distribution of the AroCell TK 210™ ELISA in the United States and Canada. Diapharma sells tests and instrumentation for the diagnostic and research fields and provides strong technical competence and experience to ensure that their customer expectations are met. “We look forward to this new collaboration with Diapharma Group for the distribution and promotion of AroCell TK 210 ELISA in...
AroCell enters a collaboration with Dana Farber Cancer Institute
AroCell enters a collaboration with Dana Farber Cancer Institute Today AroCell announces a collaboration with Dana Faber Cancer Institute to evaluate AroCell’s TK 210 ELISA assay on CDK4/6 inhibitor treated patients. The aim of the study is to examine concordance of TK 1 concentration in serum and clinical response on treatment. In the study samples will be collected from patients treated with CDK 4/6 inhibitor palbociclib throughout the course of the treatment and the concordance between AroCell’s TK 210 ELISA assay and clinical response will be evaluated. The study will include about 2...
Report from the Annual General Meeting of AroCell AB (publ) 2019
Report from the Annual General Meeting of AroCell AB (publ) 2019 (Available inSwedish only) AroCell AB (publ) (”Bolaget”) höll idag den 16 maj 2019 i Uppsala sin årsstämma för verksamhetsåret 2018, varvid följande beslut fattades. För mer detaljerad information om innehållet i besluten hänvisas till den fullständiga kallelsen till årsstämman. Kallelse till årsstämma samt fullständiga förslag finns tillgängliga på Bolagets webbplats, Fastställande av resultat- och balansräkningÅrsstämman fastställde resultaträkningen för 2018 och balansräkningen per den 31 december 2018. Resultatdisposi...
AroCell AB (publ) Interim Report 1st January to 31st March 2019
AroCell AB (publ) Interim Report 1st January to 31st March 2019 Word from the CEO “Biomarkers will play an increasingly important role in how we identify and follow up treatments for patients with cancer in the coming years. The development of an increased individual adaptation of treatment is driven by the use of biomarkers which enable diagnosis of which tumor type the patient has and also what treatment the patient should receive. Thymidine Kinase is an important and exciting biomarker that can provide early detection of therapy response in cancer treatment, which means increased su...
AroCell expands its distribution network and signs distribution agreem...
AroCell expands its distribution network and signs distribution agreement with Inveniolife AroCell AB (publ) announce today that a distribution agreement has been signed with the Mumbai based company Inveniolife Technology Pvt. Ltd. for the promotion and distribution of the AroCell TK 210™ ELISA in India. AroCell’s TK 210 ELISA measures concentration levels of thymidine kinase 1 (TK 1) in blood samples and provides valuable information about cell proliferation and disruption in patients with cancer tumors. TK 210 ELISA may also support clinicians to optimize treatment and estimate the ris...
Notice of Annual General Meeting of Arocell ab (publ)
Notice of Annual General Meeting of Arocell ab (publ) Available in Swedish only Aktieägarna i AroCell AB (publ), org.nr 556596–6107 (”Bolaget”) kallas härmed till årsstämma torsdagen den 16 maj 2019, kl. 13 i lokalen Karin Boye på Virdings allé 32 B i Uppsala. Registreringen börjar kl. 12.30 och avbryts när stämman öppnas. Anmälan m.m. Aktieägare som önskar delta i årsstämman ska: dels upptagits som aktieägare i eget namn i den av Euroclear Sweden AB förda aktieboken avseende förhållandena fredagen den 10 maj 2019 (avstämningsdagen), ochdels anmäla sitt deltagande så att den...
AroCell establish a Scientific Advisory Board
AroCell establish a Scientific Advisory Board AroCell announces today that we have established a Scientific Advisory Board to support the company in its planned expansion for the coming years. The Scientific Advisory Board (SAB) will have the objective to support the CEO and company in various matters related to AroCell’s expansion in the field of in vitro Diagnostics (IVD). The Scientific Advisory Board will focus on scientific, clinical and regulatory matters relating to AroCell’s expansion into the EU, USA and other new markets. The first member of the SAB is Johan von Heijne, CEO ...
AroCell and Corgenix establish the measurement of Thymidine Kinase 1 u...
AroCell and Corgenix establish the measurement of Thymidine Kinase 1 using AroCell TK 210 ELISA in a CLIA-lab in the USA AroCell AB (AROC NASDAQ Stockholm) announce today, in collaboration with Corgenix (Corgenix Inc., Colorado USA) that the AroCell TK 210 ELISA kit has been validated and approved for Thymidine Kinase 1 (TK1) measurements in human samples for preclinical and clinical use at the Corgenix laboratory facility in Colorado, USA. This collaboration will make AroCell’s patented biomarker assay available both as a service and as in the already existing AroCell TK 210 ELISA kit for...
AroCell´s 2018 Annual Report published
AroCell´s 2018 Annual Report published AroCell today announces that the Annual Report for 2018 is now available on the company’s website: . The Annual report is available on the following link: The report is available in Swedish only. This information was submitted for publication through the agency of Michael Brobjer, April 12, 2019 at 11:30. For more information:Michael Brobjer, CEOTelephone: +46(0)18 50 30 20E-mail: About AroCell AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell'...
CORRECTED VERSION of March 20, 2019 Press Release: New scientific publ...
CORRECTED VERSION of March 20, 2019 Press Release: New scientific publication from AroCell on TK 210 ELISA in prostate cancer In the corrected version of the press release we have added a link to the article. The aim of the study was to investigate the diagnostic value of the AroCell TK 210 ELISA together with free PSA, pro PSA and PHI in differentiating prostate cancer from benign urological conditions. The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index or protease-specific antigen density can improve the ability to differentiate prostate ca...
Abstract from AroCell accepted for poster presentation during AACR 201...
Abstract from AroCell accepted for poster presentation during AACR 2019 An abstract from AroCell has been accepted for poster presentation on the American Association of Cancer Research 2019 (AACR 2019) held from March 29 to April 3 in Atlanta, Georgia, USA. The Study compares AroCell TK210 ELISA with TK-Liaison assay. The study entitled “The Assay of Thymidine Kinase 1 in Sera from Subjects with Hematological and Solid Tumors with AroCell TK 210 ELISA: Comparison with TK-Liaison Assay and its Clinical Implications” by Jagarlamudi KK et al. shows that the AroCell TK 210 ELISA has a higher ...
New study results with AroCell TK 210 ELISA in prostate cancer has bee...
New study results with AroCell TK 210 ELISA in prostate cancer has been accepted for publication The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions” will be published in the peer-reviewed journal “The Prostate”. The link to the article will be made available during March when the article has been published. The aim of the study was to investigate the diagnostic value of the AroCell TK 210 ELISA together with free PSA, pro PSA and PHI in diffe...
AroCell AB (publ) Year-End Report 2018
AroCell AB (publ) Year-End Report 2018 Word from the CEO ”2018 has been an exciting year for AroCell with several major events. In April, AroCell signed a global non-exclusive license agreement with F. Hoffmann-La Roche Ltd (Roche). Roche is the market leader in diagnostics and the diagnostics part of the company has sales of just over SEK 100 billion and a global market share of around 20%. The license agreement gives Roche global sales rights for which AroCell receives royalties from future sales. Through the license agreement and the future cooperation with Roche, AroCell has very good ...
AroCell's CEO share his views on the company in a video interview
AroCell's CEO share his views on the company in a video interview Today AroCell publishes a short video interview with Michael Brobjer, CEO, and his reflections on his first months at Arocell. The video is available through the link below, AroCell website, and on Financial Hearings web channel. The video is available in Swedish, subtitles will be added shortly. Video: For more information:Michael Brobjer, CEOTelephone: +46(0)18 50 30 20E-mail: This information was submitted for publication through the agency of Michael Brobjer, February 13, 2019, at 12:00. About AroCell AroCell AB (...
AroCell launches new website
AroCell launches new website Today AroCell is launching its new website. The goal with the new website is to facilitate for our customers, business partner, and investors to find relevant information about AroCell. The website (arocell.com) informs about precision monitoring in cancer care and the potential clinical utility of measuring the concentration of TK1 during cancer treatment. Thymidine kinase 1 (TK1) is a potential biomarker during cancer treatment. The determination of the TK1 concentration in serum is simple using AroCell TK 210 ELISA, by using a blood sample from the patient...
AroCell is a member of SwedenBIO
AroCell is a member of SwedenBIO AroCell became this week a member of SwedenBIO, an industry organization for Swedish Life Science companies. The purpose of the membership is to take part in the broad life science development in Sweden and to participate in SwedenBIOs networks and network meetings. AroCell develops a biomarker test that can support the treatment, prognosis, and follow-up of cancer patients. SwedenBIO has a large network that includes everything from researchers, life science companies, financiers and various service companies working together for a competitive life scie...
AroCell signs distribution agreement with Gongyingshi in China for Aro...
AroCell signs distribution agreement with Gongyingshi in China for AroCell TK 210 ELISA AroCell AB (publ) announced today that a distribution agreement has been signed with the Beijing based company Gongyingshi for the promotion and distribution of the AroCell TK 210™ ELISA in China. The pharmaceutical and biotechnological industries are growing rapidly in China making it an attractive market for innovative biomarker assays such the AroCell TK 210 ELISA. Our TK 210 ELISA measures concentration levels of thymidine kinase 1 (TK 1) in blood samples and provides valuable information about ce...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.